Multi-member SMSFs: What to prepare for ahead of the next financial year smsfadviser.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from smsfadviser.com Daily Mail and Mail on Sunday newspapers.
OSE Immunotherapeutics Receives Authorization for Phase 1 Clinical Trial of its Multi-Target Multi-Variant COVID-19 Vaccine
CoVepiT is a SARS-COV-2 vaccine activating T cell defenses through CD8 T-cell multi-epitope responses.
CoVepiT epitopes are selected from 11 viral protein targets and designed to cover all initial and new emerging SARS-CoV-2 variants.
CoVepiT, as second-generation vaccine, potentially provides long-term cellular immunity with memory T cells.
Regulatory News:
OSE Immunotherapeutics (ISIN: FR0012127173; Mnemo: OSE) today announced that the Belgian Federal Agency for Medicines and Health Products (
Agence Fédérale des Médicaments et des Produits de Santé AFMPS) and the Belgian Ethics Committee approved the Phase 1 trial evaluating its COVID-19 vaccine, named CoVepiT, on 48 healthy volunteers. First subjects are expected to be enrolled shortly.
Velodyne Lidar, Inc.: Velodyne Lidar Announces Multi-Year Agreement With AGM Systems LLC
AGM Systems Launches New Velodyne Lidar-Based UAV Mapping Solution for Leading Energy Companies Worldwide Velodyne Lidar, Inc. (Nasdaq: VLDR, VLDRW) today announced a multi-year agreement with AGM Systems LLC, which provides state-of-the-art hardware and software technology for the collection, processing and analysis of air and mobile mapping data. AGM Systems will utilize Velodyne s Ultra Puck lidar sensor in their new AGM-MS3 Unmanned Aerial Vehicle (UAV) mapping solution. This solution is their second generation of one of the most popular UAV lidar scanning technologies for mapping in Russia. AGM Systems serves global leaders in the energy sector with its multi-functional, high performance technology based on Velodyne s lidar.